BioNTech SE BNTX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.09B | 3.27B | 3.32B | 3.53B | 3.13B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.09B | 3.27B | 3.32B | 3.53B | 3.13B |
| Cost of Revenue | 722.23M | 696.12M | 700.76M | 607.84M | 631.14M |
| Gross Profit | 2.37B | 2.57B | 2.62B | 2.92B | 2.49B |
| SG&A Expenses | 833.76M | 759.65M | 710.12M | 597.28M | 589.12M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 1.26B | 1.01B | 972.39M | 805.32M | 376.69M |
| Total Operating Expenses | 5.27B | 4.94B | 4.76B | 4.45B | 3.98B |
| Operating Income | -2.18B | -1.68B | -1.44B | -921.19M | -859.63M |
| Income Before Tax | -1.90B | -1.36B | -1.16B | -575.80M | -430.21M |
| Income Tax Expenses | 66.33M | 92.14M | 103.34M | 57.46M | -48.29M |
| Earnings from Continuing Operations | -1.97K | -1.45K | -1.26K | -633.26 | -381.92 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.97B | -1.45B | -1.26B | -633.26M | -381.92M |
| EBIT | -2.18B | -1.68B | -1.44B | -921.19M | -859.63M |
| EBITDA | -1.54B | -1.29B | -1.15B | -545.36M | -580.20M |
| EPS Basic | -7.82 | -5.87 | -5.23 | -2.63 | -1.58 |
| Normalized Basic EPS | -4.36 | -3.23 | -2.85 | -1.31 | -0.87 |
| EPS Diluted | -7.82 | -5.87 | -5.23 | -2.63 | -1.60 |
| Normalized Diluted EPS | -4.36 | -3.23 | -2.85 | -1.31 | -0.88 |
| Average Basic Shares Outstanding | 989.79M | 978.08M | 965.14M | 961.42M | 963.84M |
| Average Diluted Shares Outstanding | 989.79M | 978.08M | 965.14M | 961.42M | 966.82M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |